[Adobe Stock]
At its annual re:Invent event, Amazon Web Services (AWS) announced expanded alliances with two leading drug developers, Amgen and Merck, to create generative artificial intelligence (AI) technologies aimed at accelerating drug discovery and increasing efficiencies in manufacturing processes.Merck has been working with AWS and Accenture for several years whereas Amgen and AWS have collaborated for more than a decade.
Reflecting on AWS’s presence in the life sciences, Dan Sheeran, general manager of healthcare and life sciences at AWS, noted the company works with thousands of global healthcare and life sciences customers, including nine of the top 10 pharma companies.
“Healthcare and life sciences organizations are increasingly turning to AWS and technology as a business differentiator—especially with the explosion of generative AI,” Sheeran said. “Our pharma c…